Advanced ER+, HER2-Negative Breast Cancer
1 clinical trials · Condition
◉ Watch Advanced ER+, HER2-Negative Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer (NCT02338349) | Stemline Therapeutics, Inc. | 2015-01-01 |
Track Advanced ER+, HER2-Negative Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.